Drug & intervention
lurbinectedin
RxCUI 2374729
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Clinical trials
26 shownA Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLCNCT07459634 · 2026-11-30
RECRUITINGLurbinectedin With Osimertinib in Transformed Small Cell Lung CancerNCT07153055 · 2026-08-01
RECRUITINGA Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung CancerNCT07365241 · 2026-07-02
RECRUITINGBiomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLCNCT06681220 · 2026-02-23
RECRUITINGA Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung CancerNCT07155174 · 2025-11-25
RECRUITINGMaintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLCNCT06497530 · 2024-12-01
RECRUITINGLurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLCNCT06496048 · 2024-09-14
RECRUITINGLurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)NCT06228066 · 2024-06-13
RECRUITINGA Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerNCT06203210 · 2024-05-21
RECRUITINGA Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)NCT05652686 · 2023-09-05
RECRUITINGDose Attenuated Chemotherapy in Compromised Patients With Lung CancerNCT05800587 · 2023-02-22
RECRUITINGStudy of Trilaciclib and LurbinectidinNCT05578326 · 2022-10-12
RECRUITINGPalliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung CancerNCT05244239 · 2022-07-27
RECRUITINGLurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung CancerNCT07640932 · 2026-11-01
NOT_YET_RECRUITINGAn Exploratory Study of Lurbinectedin With Radiotherapy in SCLC With Single-lesion Progression After First Course TreatmentNCT06501976 · 2025-12-31
ACTIVE_NOT_RECRUITINGAn Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular TypingNCT07141771 · 2025-12-31
NOT_YET_RECRUITINGStudy Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung CancerNCT05740566 · 2023-05-31
ACTIVE_NOT_RECRUITINGClinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)NCT05153239 · 2022-07-22
COMPLETEDRW Effectiveness of Lurbinectedin in Extensive Stage SCLCNCT05285033 · 2022-04-01
COMPLETEDA Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung CancerNCT05091567 · 2021-11-18
ACTIVE_NOT_RECRUITINGLurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine CancersNCT04802174 · 2021-06-01
ACTIVE_NOT_RECRUITINGDurvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung CancerNCT04607954 · 2020-12-04
ACTIVE_NOT_RECRUITINGImmune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLCNCT04610658 · 2020-11-23
TERMINATEDLurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.NCT04358237 · 2020-09-21
COMPLETEDLurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.NCT03213301 · 2017-09-28
COMPLETEDA Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USANCT04291937
APPROVED_FOR_MARKETINGConditions being studied
Small-Cell Lung Cancer5Relapsed Small Cell Lung Cancer4Small Cell Lung Cancer4Lung Cancer2Recurrent Small Cell Lung Cancer2Small Cell Lung Cancer (SCLC)2Small Cell Lung Carcinoma2Advanced Solid Tumor1Carcinoma, Small Cell Lung1Extensive Stage Lung Small Cell Carcinoma1Extensive-Stage Small Cell Lung Cancer1Extensive-stage Small-cell Lung Cancer1Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)1Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)1High Grade Neuroendocrine Cancers1High Grade Neuroendocrine Tumors of the Urinary Tract1Large Cell Neuroendocrine Cancer (LCNEC)1Malignant Pleural Mesothelioma, Advanced1Neuroendocrine Carcinomas (NEC)1Neuroendocrine Prostate Cancer (NEPC)1
Research locations
Leading sponsors
AbbVie2Cancer Institute and Hospital, Chinese Academy of Medical Sciences2Jazz Pharmaceuticals2National Cancer Institute (NCI)2Amgen1Antonio Calles Blanco1Daiichi Sankyo1Emory University1Fox Chase Cancer Center1Guangzhou Institute of Respiratory Disease1H. Lee Moffitt Cancer Center and Research Institute1Hoffmann-La Roche1Intergroupe Francophone de Cancerologie Thoracique1Luye Pharma Group Ltd.1Mayo Clinic1
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.